Mike Matson evaluated two earlier negative bits of information along with Thursday's revenue and earnings-per-share miss to conclude that Medtronic's stock, which has held up despite recent market swings, needs to be downgraded to a "hold" from a "buy".
Pairing rheumatology expertise with the latest digital technologies, this app helps patients manage their treatment regimen with innovative and intuitive features.
By Vinita Kailasanath and Sora Park Friday, May 27, 2022 4:14 PM
In December, the FDA published a draft guidance providing its recommendations on the use of digital health data acquisition in clinical investigations, signaling that regulatory acceptance of digital endpoints in support of drug approval may occur in the short-term.
Pfizer and BioNTech reported positive clinical data for a Covid-19 booster in children younger than 5, results released ahead of a June FDA advisory committee meeting scheduled to discuss the use of that vaccine and Moderna's in kids. In other Covid news this week, the CDC issued a health advisory for Pfizer's antiviral Paxlovid and a respiratory failure drug for Covid-19 flunked its clinical trial.
Mike Matson evaluated two earlier negative bits of information along with Thursday's revenue and earnings-per-share miss to conclude that Medtronic's stock, which has held up despite recent market swings, needs to be downgraded to a "hold" from a "buy".
No comments